These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 27537073)

  • 1. Update on TNF Inhibitors in Dermatology.
    Sobell JM
    Semin Cutan Med Surg; 2016 Jun; 35(6 Suppl):S104-6. PubMed ID: 27537073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors: An update on infliximab.
    Brunasso AM; Massone C
    Acta Derm Venereol; 2011 Jan; 91(1):70-1. PubMed ID: 21103830
    [No Abstract]   [Full Text] [Related]  

  • 3. Tumor necrosis factor alpha inhibitors for the treatment of dermatologic diseases.
    Trent JT; Kerdel FA
    Dermatol Nurs; 2005 Apr; 17(2):97-107. PubMed ID: 15916184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of biologics in the treatment of hidradenitis suppurativa: a review of the Henry Ford Hospital experience.
    Zhang J; Reeder VJ; Hamzavi IH
    Br J Dermatol; 2014 Dec; 171(6):1600-2. PubMed ID: 24931223
    [No Abstract]   [Full Text] [Related]  

  • 5. Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa.
    Delobeau M; Abdou A; Puzenat E; Deveza E; Biver-Dalle C; van de Laak A; Roche-Kubler B; Vuitton L; Koch S; Wendling D; Aubin F
    J Dermatolog Treat; 2016; 27(3):251-3. PubMed ID: 26368546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paradoxical psoriasiform reactions to antitumour necrosis factor-α drugs in hidradenitis suppurativa.
    Dequidt L; Cogrel O; Guillet S; Milpied B; Darrigade AS; Beylot-Barry M; Pham-Ledard A
    Br J Dermatol; 2018 Jan; 178(1):281-283. PubMed ID: 28444990
    [No Abstract]   [Full Text] [Related]  

  • 7. The Use of TNFα Inhibitors in Treating Pediatric Skin Disorders.
    Nguyen QD; Starling CT; Hebert AA
    Paediatr Drugs; 2020 Jun; 22(3):311-319. PubMed ID: 32350817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of hidradenitis suppurativa with biological therapy: report of four cases and review of the literature.
    Bahillo Monné C; Honorato Guerra S; Schoendorff Ortega C; Gargallo Quintero AB
    Dermatology; 2014; 229(4):279-87. PubMed ID: 25472035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumour necrosis factor-α therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013.
    Sbidian E; Hotz C; Seneschal J; Maruani A; Amelot F; Aubin F; Paul C; Beylot Barry M; Humbert P; Dupuy A; Caux F; Dupin N; Modiano P; Lepesant P; Ingen-Housz-Oro S; Mahé E; Bachelez H; Chosidow O; Wolkenstein P
    Br J Dermatol; 2016 Mar; 174(3):667-70. PubMed ID: 26406350
    [No Abstract]   [Full Text] [Related]  

  • 10. Flexural or inverse psoriasis in a patient with hidradenitis suppurativa receiving treatment with infliximab.
    Nuño-González A; Dehesa L; Ricotti C; Kerdel F
    Actas Dermosifiliogr; 2012 Dec; 103(10):936-7. PubMed ID: 23149048
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn's disease.
    Rosi YL; Lowe L; Kang S
    J Dermatolog Treat; 2005 Feb; 16(1):58-61. PubMed ID: 15897171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric psoriasis: updates in biologic therapies.
    Sukhatme SV; Gottlieb AB
    Dermatol Ther; 2009; 22(1):34-9. PubMed ID: 19222515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etanercept: effective in the management of hidradenitis suppurativa.
    Cusack C; Buckley C
    Br J Dermatol; 2006 Apr; 154(4):726-9. PubMed ID: 16536817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview of developing TNF-α targeted therapy for the treatment of psoriasis.
    Campa M; Ryan C; Menter A
    Expert Opin Investig Drugs; 2015; 24(10):1343-54. PubMed ID: 26289788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?
    Abdalla T; Lowes MA; Kaur N; Micheletti RG; Steinhart AH; Alavi A
    Am J Clin Dermatol; 2021 Mar; 22(2):139-147. PubMed ID: 33398848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience of the use of adalimumab in the management of hidradenitis suppurativa. Comparison of response rates with Crohn disease.
    Moyano B; Clemente A; Marín-Jiménez I; Martorell A
    Actas Dermosifiliogr; 2016 Sep; 107 Suppl 2():43-50. PubMed ID: 28081769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten years of infliximab: its role in dermatology.
    Mrowietz U; Reich K
    Eur J Pharmacol; 2009 Nov; 623 Suppl 1():S10-6. PubMed ID: 19837058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of recalcitrant gluteal hidradenitis suppurativa with brodalumab after anti-TNF failure.
    Arenbergerova M; Arenberger P; Marques E; Gkalpakiotis S
    Int J Dermatol; 2020 Jun; 59(6):733-735. PubMed ID: 32012238
    [No Abstract]   [Full Text] [Related]  

  • 19. Interleukin 6 and high-sensitivity C-reactive protein are potential predictive markers of response to infliximab in hidradenitis suppurativa.
    Montaudié H; Seitz-Polski B; Cornille A; Benzaken S; Lacour JP; Passeron T
    J Am Acad Dermatol; 2017 Jan; 76(1):156-158. PubMed ID: 27986139
    [No Abstract]   [Full Text] [Related]  

  • 20. Navigating Targeted Therapeutics in Dermatology: Biologics and Small Molecules.
    Costello C; Maarouf M; Shi V
    J Drugs Dermatol; 2018 Dec; 17(12):1330-1332. PubMed ID: 30586268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.